David A. Cory - 29 Jul 2021 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Sriram Ryali, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
29 Jul 2021
Net transactions value
$0
Form type
4
Filing time
30 Jul 2021, 16:29:35 UTC
Next filing
11 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +48,750 $0.000000 48,750 29 Jul 2021 Common Stock 48,750 $8.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal monthly installments over 36 months measured from July 29, 2021 subject to Reporting Person's continuous service status as of each such date.